GERI-BP001 compounds, new inhibitors of acyl-CoA: cholesterol acyltransferase from Aspergillus fumigatus F37. I. Production, isolation, and physico-chemical and biological properties

J Antibiot (Tokyo). 1995 Aug;48(8):751-6. doi: 10.7164/antibiotics.48.751.

Abstract

GERI-BP001 compounds, new inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT), were isolated from a culture broth of Aspergillus fumigatus F37 by acetone extraction, EtOAc extraction, SiO2 column chromatography, and reverse phase HPLC. GERI-BP001 M, A, and B inhibit ACAT activity in an enzyme assay system using rat liver microsomes by 50% at concentrations of 42, 94, and 40 microM, respectively.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aspergillus fumigatus
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / isolation & purification*
  • Enzyme Inhibitors / pharmacology
  • Fermentation
  • Microbial Sensitivity Tests
  • Microsomes, Liver / drug effects
  • Pyridines / chemistry
  • Pyridines / isolation & purification*
  • Pyridines / pharmacology
  • Rats
  • Sesquiterpenes / chemistry
  • Sesquiterpenes / isolation & purification*
  • Sesquiterpenes / pharmacology
  • Sterol O-Acyltransferase / antagonists & inhibitors*

Substances

  • Enzyme Inhibitors
  • GERI-BP001 A
  • GERI-BP001 B
  • GERI-BP001 M
  • Pyridines
  • Sesquiterpenes
  • Sterol O-Acyltransferase